PGG glucan(PGG glucan) - 药物靶点：CD11b x CD32A_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

聚合物

别名

Betafectin、Imprime、Imprime PGG

+ [4]

靶点

CD11b x CD32A

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症

晚期非小细胞肺癌KRAS 野生型结直肠癌皮肤黑色素瘤+ [2]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

Hibercell, Inc.初创企业

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 PGG glucan 相关的临床试验

NCT05484011 / Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

Hibercell, Inc.初创企业

[+1]

NCT05159778 / Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

Hibercell, Inc.初创企业

[+1]

CTRI/2021/10/037380 / Not yet recruiting临床3期

An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid-19 caused by SARS-COV2 (B-COV)

开始日期2021-10-25

申办/合作机构-

100 项与 PGG glucan 相关的临床结果

登录后查看更多信息

100 项与 PGG glucan 相关的转化医学

登录后查看更多信息

100 项与 PGG glucan 相关的专利（医药）

登录后查看更多信息

238

项与 PGG glucan 相关的文献（医药）

2024-12-09·Journal of biomolecular structure & dynamics

Structural insights into modeling of hepatitis B virus reverse transcriptase and identification of its inhibitors from potential medicinal plants of Western Ghats: an in silic o and in vitro study

Article

作者: Roy, Subarna ; Deshpande, Sanjay H. ; Charla, Rajitha ; Harish, Darasaguppe R. ; Hegde, Harsha V. ; Jalalpure, Sunil S. ; Patil, Vishal S. ; Vetrivel, Umashankar ; Bhandare, Vishwambhar Vishnu

The present study was proposed to model full-length HBV-RT and investigate the intermolecular interactions of known inhibitor and libraries of phytocompounds to probe the potential natural leads by in silico and in vitro studies. Homology modeling of RT was performed by Phyre2 and Modeller and virtual screening of ligands implemented through POAP pipeline. Molecular dynamics (MD) simulation (100 ns) and MM-GBSA calculations were performed using Schrodinger Desmond and Prime, respectively. Phytocompounds probable host protein targets gene set pathway enrichment and network analysis were executed by KEGG database and Cytoscape software. Prioritized plant extracts/enriched fraction LC-MS analysis was performed and along with pure compound, RT inhibitory activity, time-dependent HBsAg and HBeAg secretion, and intracellular HBV DNA, and pgRNA by qRT-PCR was performed in HepG2.2.15 cell line. Among the screened chemical library of 268 phytocompounds from 18 medicinal plants, 15 molecules from Terminalia chebula (6), Bidens pilosa (5), and Centella asiatica (4)) were identified as potential inhibitors of YMDD and RT1 motif of HBV-RT. MD simulation demonstrated stable interactions of 15 phytocompounds with HBV-RT, of which 1,2,3,4,6-Pentagalloyl Glucose (PGG) was identified as lead molecule. Out of 15 compounds, 11 were predicted to modulate 39 proteins and 15 molecular pathways associated with HBV infection. TCN and TCW (500 µg/mL) showed potent RT inhibition, decreased intracellular HBV DNA, and pgRNA, and time-dependent inhibition of HBsAg and HBeAg levels compared to PGG and Tenofovir Disoproxil Fumarate. We propose that the identified lead molecules from T. chebula as promising and cost-effective moieties for the management of HBV infection.Communicated by Ramaswamy H. Sarma.

2024-10-01·Small

Dual‐Drug Nanomedicine Assembly with Synergistic Anti‐Aneurysmal Effects via Inflammation Suppression and Extracellular Matrix Stabilization

Article

作者: Peng, Cheng ; Wang, Hai Yang ; Zhu, Zi Jia ; Zu, Hong Lin ; Zhou, Wen Hu ; Wang, Qing Shan ; Yao, Ye ; Yue, Jie ; Zhuang, Pei Pei ; Peng, Chao ; Peng, Ying

Abstract:

Abdominal aortic aneurysm (AAA) represents a critical cardiovascular condition characterized by localized dilation of the abdominal aorta, carrying a significant risk of rupture and mortality. Current treatment options are limited, necessitating novel therapeutic approaches. This study investigates the potential of a pioneering nanodrug delivery system, RAP@PFB, in mitigating AAA progression. RAP@PFB integrates pentagalloyl glucose (PGG) and rapamycin (RAP) within a metal–organic‐framework (MOF) structure through a facile assembly process, ensuring remarkable drug loading capacity and colloidal stability. The synergistic effects of PGG, a polyphenolic antioxidant, and RAP, an mTOR inhibitor, collectively regulate key players in AAA pathogenesis, such as macrophages and smooth muscle cells (SMCs). In macrophages, RAP@PFB efficiently scavenges various free radicals, suppresses inflammation, and promotes M1‐to‐M2 phenotype repolarization. In SMCs, it inhibits apoptosis and calcification, thereby stabilizing the extracellular matrix and reducing the risk of AAA rupture. Administered intravenously, RAP@PFB exhibits effective accumulation at the AAA site, demonstrating robust efficacy in reducing AAA progression through multiple mechanisms. Moreover, RAP@PFB demonstrates favorable biosafety profiles, supporting its potential translation into clinical applications for AAA therapy.

2024-05-01·International journal of biological macromolecules

Discovery of a botanical compound as a broad-spectrum inhibitor against gut microbial β-glucuronidases from the Tibetan medicine Rhodiola crenulata

Article

作者: Hou, Xu-Dong ; Sun, Jian-Ming ; Zhang, Shou-De ; Ge, Guang-Bo ; Huang, Jian ; Ma, Li-Juan ; Zhang, Ya-Ni ; Guo, Zhao-Bin ; Zhu, Guang-Hao ; Hou, Jie ; Chen, Lu

Gut microbial β-glucuronidases (gmβ-GUS) played crucial roles in regulating a variety of endogenous substances and xenobiotics on the circulating level, thus had been recognized as key modulators of drug toxicity and human diseases. Inhibition or inactivation of gmβ-GUS enzymes has become a promising therapeutic strategy to alleviate drug-induced intestinal toxicity. Herein, the Rhodiola crenulata extract (RCE) was found with potent and broad-spectrum inhibition on multiple gmβ-GUS enzymes. Subsequently, the anti-gmβ-GUS activities of the major constituents in RCE were tested and the results showed that 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (PGG) acted as a strong and broad-spectrum inhibitor on multiple gmβ-GUS (including EcGUS, CpGUS, SaGUS, and EeGUS). Inhibition kinetic assays demonstrated that PGG effectively inhibited four gmβ-GUS in a non-competitive manner, with the K_i values ranging from 0.12 μM to 1.29 μM. Docking simulations showed that PGG could tightly bound to the non-catalytic sites of various gmβ-GUS, mainly via hydrogen bonding and aromatic interactions. It was also found that PGG could strongly inhibit the total gmβ-GUS activity in mice feces, with the IC₅₀ value of 1.24 μM. Collectively, our findings revealed that RCE and its constituent PGG could strongly inhibit multiple gmβ-GUS enzymes, suggesting that RCE and PGG could be used for alleviating gmβ-GUS associated enterotoxicity.

9

项与 PGG glucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 PGG glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS 野生型结直肠癌	临床3期	美国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	法国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	德国	Hibercell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床3期	波多黎各	Hibercell, Inc.初创企业	2011-04-01
乳腺癌	临床2期	-	Hibercell, Inc.初创企业	2022-04-28
皮肤黑色素瘤	临床2期	美国	Hibercell, Inc.初创企业	2021-08-15
晚期非小细胞肺癌	临床2期	美国	Hibercell, Inc.初创企业	2009-08-01
晚期非小细胞肺癌	临床2期	德国	Hibercell, Inc.初创企业	2009-08-01
转移性胰腺导管腺癌	临床1期	美国	Hibercell, Inc.初创企业	2022-12-15
转移性胰腺腺癌	临床1期	美国	Hibercell, Inc.初创企业	2022-12-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	艱夢遞夢壓鏇繭範蓋顧(願糧糧鹹鬱窪鬱積鏇膚) = 齋壓獵鏇網廠簾範壓製淵壓願構鏇鹹艱觸範醖 (壓製餘獵鬱窪膚範齋鏇 ) 更多	-	2022-06-02
NCT03003468 (BTCRC-LUN15-017, WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	淵餘淵餘觸願艱鏇齋襯(願顧鬱鹽衊糧鑰鑰夢窪) = 餘壓膚觸窪簾選壓鏇鏇齋淵範鑰鬱鬱膚範糧選 (鹹糧築淵夢襯窪構醖壓, 1.28 ~ 27.8) 更多	不佳	2021-09-08
				Pembro+Imprime PGG (phase II)	淵餘淵餘觸願艱鏇齋襯(願顧鬱鹽衊糧鑰鑰夢窪) = 憲襯壓構醖構製夢鑰獵齋淵範鑰鬱鬱膚範糧選 (鹹糧築淵夢襯窪構醖壓, 1.35 ~ 5.13) 更多
NCT00912327 (Pubmed \| Clin Colorectal Cancer) 人工标引	临床2期	KRAS 突变结直肠癌 KRAS Mutation	18	Imprime PGG+Cetuximab	鹽觸廠構夢選鑰窪壓顧(艱遞繭築網膚選齋鏇鏇) = fatigue 38.9%, infusion reaction 22.2%, and headache 22.2%. 壓鏇鑰齋網願壓夢選網 (範糧構選廠積襯廠醖築 )	积极	2016-09-01
AAI2016	N/A	-	-	Anti-PD1 antibody	積蓋艱簾鑰築鬱願鬱憲(夢範選壓獵壓膚鹹鏇簾) = increased proliferation in response to CD3/CD28 stimulation 遞憲襯壓膚廠膚齋餘夢 (獵願鑰繭鬱糧選窪窪廠 )	-	2016-05-01
				Imprime and Anti-PD1 combination
NCT00542464 (Pubmed \| Invest New Drugs) 人工标引	临床1期	-	36	BTH1677	願構築顧蓋襯鹹鏇築醖(淵鹹餘簾網夢鹽願蓋夢) = 夢憲襯夢構齋築製餘餘窪願窪襯憲鹽壓網築積 (築膚衊構餘窪壓蓋鬱範 )	积极	2016-04-01
				Placebo	-
NCT00874107 (WCLC2015)	临床2期	-	92	Imprime PGG + Carboplatin/Paclitaxel + Bevacizumab	憲餘鹹顧願繭鏇築齋壓(觸糧積願壓鑰遞簾積鹽) = 製鑰齋遞蓋夢積壓觸築選窪願構製遞鏇鬱齋獵 (淵範構積襯夢廠糧鏇膚 ) 更多	-	2015-09-09
				Carboplatin/Paclitaxel + Bevacizumab	憲餘鹹顧願繭鏇築齋壓(觸糧積願壓鑰遞簾積鹽) = 鑰衊糧廠繭遞構鹹齋窪選窪願構製遞鏇鬱齋獵 (淵範構積襯夢廠糧鏇膚 ) 更多
NCT00874848 \| NCT00874107 (ASCO2015)	临床2期	转移性非小细胞肺癌	177	Imprime PGG	簾艱觸鹽觸繭淵醖繭醖(範製齋艱廠顧鏇餘廠鬱) = 醖窪構膚淵獵鏇鹽憲製網齋夢獵夢鏇醖蓋艱選 (範衊繭餘膚鹹醖壓餘鹹 ) 更多	-	2015-05-20
				Control	夢壓廠鏇壓簾遞鏇鏇夢(醖夢壓糧廠簾獵鹽鬱網) = 醖廠鑰糧艱糧齋壓夢鏇憲憲餘餘艱鏇淵鏇糧糧 (壓齋艱醖襯鹹廠蓋顧餘 ) 更多
NCT00874107 (ASCO2015)	临床2期	转移性非鳞状非小细胞肺癌	92	Imprime PGG	襯範膚艱艱蓋鹽願鹽簾(範夢構齋鬱簾顧積願顧) = 餘繭憲膚簾衊窪範鹹繭範廠膚願遞蓋蓋築遞願 (壓蓋鏇衊遞艱鬱顧糧夢 ) 更多	-	2015-05-20
				Standard of care frontline treatment (carboplatin/paclitaxel and bevacizumab)	襯範膚艱艱蓋鹽願鹽簾(範夢構齋鬱簾顧積願顧) = 鹽鏇艱遞鏇醖遞簾窪醖範廠膚願遞蓋蓋築遞願 (壓蓋鏇衊遞艱鬱顧糧夢 ) 更多
NCT00874848 (ASCO2014)	临床2期	非小细胞肺癌	90	Control	夢繭餘鬱壓築鑰糧窪選(襯觸遞選願遞淵夢鑰積) = 窪醖蓋鹹醖範簾艱糧壓顧鹽遞艱糧艱醖製繭窪 (選顧齋獵簾襯艱積餘範 ) 更多	-	2014-05-20
				Imprime PGG	夢繭餘鬱壓築鑰糧窪選(襯觸遞選願遞淵夢鑰積) = 夢窪餘鹽製願鹽網網願顧鹽遞艱糧艱醖製繭窪 (選顧齋獵簾襯艱積餘範 ) 更多
ASCO2010	临床2期	晚期结直肠腺癌	22	Imprime PGG + cetuximab + irinotecan	遞觸鏇淵構遞範憲齋廠(簾構糧構齋願築鏇鹽夢) = 46% 鹹夢獵蓋網鏇餘憲鑰顧 (簾築廠範齋廠範遞糧鬱 ) 更多	-	2010-05-20
				Imprime PGG + cetuximab